Short Interest in Decoy Therapeutics (NASDAQ:DCOY) Drops By 57.7%

Decoy Therapeutics (NASDAQ:DCOY) was the target of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 10,675 shares, a decline of 57.7% from the July 30th total of 25,246 shares. Approximately 1.7% of the shares of the company are short sold. Based on an average daily volume of 34,121 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, June 12th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $30.00.

Decoy Therapeutics Stock Performance

Decoy Therapeutics stock traded down $0.07 on Friday, reaching $2.90. The company’s stock had a trading volume of 33,351 shares, compared to its average volume of 27,218. The business’s fifty day moving average price is $4.93 and its 200 day moving average price is $6.20. The company has a market cap of $1.91 million, a price-to-earnings ratio of -0.10 and a beta of 0.64. Decoy Therapeutics has a twelve month low of $2.85 and a twelve month high of $70.80.

Decoy Therapeutics (NASDAQ:DCOY) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($4.46) earnings per share (EPS) for the quarter. The company had revenue of $0.23 million during the quarter. As a group, equities analysts forecast that Decoy Therapeutics will post -12.97 earnings per share for the current year.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.